首页 | 本学科首页   官方微博 | 高级检索  
检索        

DICE方案与CHOP方案治疗中高度恶性非霍奇金淋巴瘤的随机对照研究
引用本文:王文武,欧阳学农,陈樟树,彭永海,解方为,余宗阳.DICE方案与CHOP方案治疗中高度恶性非霍奇金淋巴瘤的随机对照研究[J].中国癌症杂志,2006,16(9):748-750.
作者姓名:王文武  欧阳学农  陈樟树  彭永海  解方为  余宗阳
作者单位:南京军区福州总医院肿瘤科,国家中西医结合肿瘤重点专科,福建,福州,350025
摘    要:背景与目的:长期以来,CHOP方案被认为是治疗中、高度恶性非霍奇金淋巴瘤(non—Hodgkin,slym—phoma,NHL)的基本方案,近年有文献报道DICE方案可以提高中、高度恶性NHL的疗效。本研究中我们比较DICE方案与CHOP方案治疗中、高度恶性NHL的疗效与安全性,为中、高度恶性NHL的规范治疗提供依据。方法:选择经病理学或组织学证实的中、高度恶性NHL的患者74例,按信封法随机分为DICE组与CHOP组两组,分别采用上述两种方案治疗。结果:DICE组CR15例(40.5%),PR14例(37.8%),缓解率RR(CR+PR)为78.3%(29/37);CHOP组CR11例(29.7%),PR10例(27.0%),RR为56.7%(21/37);两组比较有显著性差异(P〈0.05)。DICE组的1、3、5年生存率分别为89.2%、76.0%和46.7%,CHOP组分别为81.2%、52.6%和36.4%。两组比较有显著性差异(P〈0.05)。两组出现的主要不良反应为Ⅲ/Ⅳ度粒细胞和血小板减少及恶心等,两组比较无显著性差异(P〉0.05)。结论:与CHOP方案相比,DICE方案疗效较好,不良反应可以耐受,但是否可作为治疗中、高度恶性NHL的首选方案之一,值得进一步研究。

关 键 词:非霍奇金淋巴瘤  联合化疗  对照研究
文章编号:1007-3639(2006)09-0748-03
收稿时间:2006-03-27
修稿时间:2006-06-02

Comparison of DICE and CHOP regimen in the treatment of intermediate and high grade Non-Hodgkin's lymphoma-a clinical phase Ⅲ trial
WANG Wen-wu,OU-YANG Xue-nong,CHENG Zhang-shu,PENG Yong-hai,XIE Fang-wei,YU Zong-yang.Comparison of DICE and CHOP regimen in the treatment of intermediate and high grade Non-Hodgkin''''s lymphoma-a clinical phase Ⅲ trial[J].China Oncology,2006,16(9):748-750.
Authors:WANG Wen-wu  OU-YANG Xue-nong  CHENG Zhang-shu  PENG Yong-hai  XIE Fang-wei  YU Zong-yang
Abstract:Background and purpose:CHOP regimen is the standard modality for the treatment of intermediate and high grade non-Hodgkin's lymphoma (NHL). Previous reports showed that DICE regimen might improve response rate of patients with intermediate and high grade NHL. This study compares the efficacy and safety of DICE and CHOP regimens in the treatment of this disease so that it could provide a rationale for evident-based treatment. Methods:A total of 74 patients with histopathologically proved intermediate or high malignant NHL were randomized into trial group (37 patients treated with DICE regimen) and control group (37 patients treated with CHOP regimen). Survival analysis was performed by Kaplan-Meier method.Results:The complete response rate, partial response rate, and total response rate were significantly higher in DICE group than in CHOP group (40.5% vs. 29.7%, 37.8% vs. 27.0%, and 78.3% vs. 56.7%, respectively, P<0.05). The 1-, 3-, and 5-year survival rates were significantly higher in DICE group than in CHOP group (89.2% vs. 81.2%, 76.0% vs. 52.6%%, and 46.7% vs. 36.4%, respectively,P<0.05). The major side effects were leucopenia, thrombocytopenia, and nausea in both groups, there were no significant differences in terms of morbidity or side effects in both groups. Three episodes of clinical cystitis or gross haematuria seem to be associated with the treatment by the DICE regimen.Conclusions:The results show higher efficacy of DICE regimen over CHOP regimen. DICE regimen may prolong survival time of patients with intermediate or highly malignant NHL.
Keywords:non-Hodgkin's lymphoma  combined chemotherapy  comparative trial
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号